

Attorney Docket No. AH / Le A 36 807

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Gert Daube, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/EP2004/008629

Title: Novel Use of Quinolone Antibiotics

**MAIL STOP PCT  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450**

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
WITHIN THREE MONTHS OF DATE OF NATIONAL STAGE ENTRY  
37 C.F.R. 1.97(b)(2)**

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying form(s) PTO/SB/08A-B [substitute for form 1449/PTO]. A copy of the International Search Report is also enclosed for your reference.


**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed concurrently with the request under 35 U.S.C. § 371(f) to begin national examination procedures.

**FEE PAYMENT**

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

  
\_\_\_\_\_  
Susan M. Pellegrino

Reg. No.: 48,972

Attorney for Applicant(s)

Bayer Pharmaceuticals Corporation  
400 Morgan Lane  
West Haven, CT 06516  
Telephone: (203) 812-6450  
Facsimile: (203) 812-6459

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**Complete if Known**

[to be assigned]

**Gert Daube**

**AH / Le A 36 807**

U. S. PATENT DOCUMENTS

[illegible]

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	[to be assigned]
				Filing Date	
				First Named Inventor	Gert Daube
				Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	AH / Le A 36 807

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	Bansal, M. B., et al., "Activity of Difloxacin (A-56619) and A-56620 against Clinical Anaerobic Bacteria In Vitro", Antimicrobial Agents and Chemotherapy, 31(4): 619-621 (April 1987)	
	R2	Coulet, M., et al., "Pharmacokinetics of ibafloxacin Following intravenous and oral administration to healthy Beagle dogs", J. Vet. Pharmacol. Therap. 25: 89-97 (2002)	
	R3	Da Silva, A. D., et al., "Biological Activity and synthetic Metodologies for the Preparation of Fluoroquinolones, A Class of Potent Antibacterial Agents", Current Medicinal Chemistry, 10(1): 21-39 (2003)	
	R4	Goldstein, E. J. C., et al., In Vitro Activities of a New Des-Fluoroquinolone, BMS 284756, and Seven Other Antimicrobial Agents Against 151 Isolates of Eikenella corrodens", Antimicrobial Agents and Chemotherapy, 46(4): 1141-1143 (April 2002)	
	R5	Granneman, G. R., et al., "Difloxacin Metabolism and Pharmacokinetics in Humans after Single Oral Doses", Antimicrobial Agents and Chemotherapy, 30(5): 689-693 (November 1986)	
	R6	Hecht, D. W., et al., "Activities of Garenoxacin (BMS-284756) and Other Agents Against Anaerobic Clinical Isolates", Antimicrobial Agents and Chemotherapy, 47(3): 910-916 (March 2003)	
	R7	McGuirk, P. R., et al. "Synthesis and Structure-Activity Relationships of 7-Diazabicycloalkylquinolones, Including Danofloxacin, a New Quinolone Antibacterial Agent for Veterinary Medicine", J. Med. Chem. 35(4): 611-620 (February 1992)	
	R8	Slots, J., "Selection of Antimicrobial Agents in Periodontal Therapy", J. Periodont. Res., 37: 389-398 (2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.